OverviewSuggest Edit

Avid Bioservices, formerly Peregrine Pharmaceuticals, is a biopharmaceutical company, which is engaged in providing contract manufacturing services for third party customers on a fee-for-service basis while also supporting its internal drug development efforts. The Company delivers pharmaceutical products through its contract manufacturing business and through licensing its development-stage immunotherapy products. Avid provides a comprehensive range of process development, high quality cGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries.

TypePublic
Founded1981
HQTustin, CA, US
Websiteavidbio.com
Employee Ratings2.8

Latest Updates

Employees (est.) (Apr 2019)211(+15%)
Job Openings30
Revenue (FY, 2020)$59.7 M(+12%)
Share Price (Sept 2021)$19
Cybersecurity ratingBMore

Key People/Management at Avid Bioservices

Joseph Carleone

Joseph Carleone

Chairman of the Board
Daniel Hart

Daniel Hart

Chief Financial Officer
Richard B. Hancock

Richard B. Hancock

Interim President and CEO
Mark Ziebell

Mark Ziebell

VP General Counsel & Corporate Secretary
Catherine MacKey

Catherine MacKey

Director
Richard Richieri

Richard Richieri

Chief Operations Officer
Show more

Avid Bioservices Office Locations

Avid Bioservices has an office in Tustin
Tustin, CA, US (HQ)
2642 Michelle Dr #200
Show all (1)

Avid Bioservices Financials and Metrics

Avid Bioservices Revenue

Avid Bioservices's revenue was reported to be $59.7 m in FY, 2020
USD

Revenue (Q3, 2021)

21.8m

Gross profit (Q3, 2021)

6.2m

Gross profit margin (Q3, 2021), %

28.4%

Net income (Q3, 2021)

2.2m

EBIT (Q3, 2021)

2.2m

Market capitalization (15-Sept-2021)

1.2b

Closing stock price (15-Sept-2021)

19.0

Cash (31-Jan-2021)

70.9m

EV

1.1b
Avid Bioservices's current market capitalization is $1.2 b.
Annual
USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

15.2m21.7m22.4m26.8m44.7m57.6m53.6m53.6m59.7m

Revenue growth, %

20%67%

Cost of goods sold

56.5m46.4m55.8m

Gross profit

(2.9m)7.2m3.9m
Quarterly
USDQ1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021

Revenue

5.7m4.2m3.3m4.3m6.1m7.0m4.7m7.4m3.9m5.5m6.3m5.7m9.7m9.5m6.7m5.6m23.4m10.7m12.6m10.2m13.8m15.3m18.3m13.6m25.4m21.1m21.8m

Cost of goods sold

11.4m9.8m11.7m14.2m15.0m12.8m16.8m14.6m15.6m

Gross profit

1.2m334.0k2.1m1.1m3.4m785.0k8.5m6.4m6.2m

Gross profit Margin, %

9%3%15%7%18%6%34%30%28%
USDQ1, 2012

Financial Leverage

2.3 x
Show all financial metrics

Avid Bioservices Operating Metrics

FY, 2016

Phase I/II Trials Products

1
Show all operating metrics

Avid Bioservices Revenue Breakdown

Embed Graph

Avid Bioservices revenue breakdown by business segment: 99.3% from Contract manufacturing services and 0.7% from Other

Avid Bioservices Cybersecurity Score

Cybersecurity ratingPremium dataset

B

87/100

SecurityScorecard logo

Avid Bioservices Online and Social Media Presence

Embed Graph

Avid Bioservices News and Updates

Global Vascular Disrupting Agents Market Report 2021-2030 with Company Profiles of AGC Biologics, Avid Bioservices, Bionomics, Mateon Therapeutics, Myrexis, VBL Therapeutics

DUBLIN, July 14, 2021 /PRNewswire/ -- The "Vascular Disrupting Agents Market, 2021-2030: Indications, Therapeutic Area, Molecules, Therapy, Route of Administration, and Regions" report has been added to ResearchAndMarkets.com's offering. The 'Vascular Disrupting Agents Market, 2021-2030...

Avid Bioservices Announces Appointment of Esther M. Alegria, Ph.D., to Board of Directors

Former SVP of Global Manufacturing at Biogen Has Nearly 30 Years of Biopharmaceutical Industry Experience Former SVP of Global Manufacturing at Biogen Has Nearly 30 Years of Biopharmaceutical Industry Experience

Avid Bioservices to Participate in KeyBanc Capital Markets Life Sciences & MedTech Investor Forum

TUSTIN, Calif., March 17, 2021 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnolog…

Avid Bioservices, Inc. Announces Pricing of $125 Million Offering of Exchangeable Senior Notes

TUSTIN, Calif., March 10, 2021 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP) (the “company”), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services…

Avid Bioservices to Report Financial Results for Third Quarter of Fiscal Year 2021 After Market Close on March 8, 2021

TUSTIN, Calif., March 01, 2021 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnolog…

Avid Bioservices Begins Phase 2 of its Myford Manufacturing Capacity Expansion Plan

Build Out of Myford Facility Will Expand Current Footprint to Include Second Manufacturing Train with Both Upstream and Downstream Processing Suites
Show more

Avid Bioservices Blogs

Avid Bioservices to Participate at Upcoming Investor Conferences

Avid Bioservices to Participate at Upcoming Investor Conferences Content Import Thu, 09/02/2021 - 16:08 Avid Bioservices to Participate at Upcoming Investor Conferences September 2, 2021 at 4:05 PM EDT This release is a backfill from a News Wire …

Avid Bioservices to Report Financial Results for First Quarter of Fiscal Year 2022 After Market Close on September 8, 2021

Avid Bioservices to Report Financial Results for First Quarter of Fiscal Year 2022 After Market Close on September 8, 2021 Content Import Wed, 09/01/2021 - 16:07 Avid Bioservices to Report Financial Results for First Quarter of Fiscal Year 2022 After Market Close on September 8, 2021 …

Avid Bioservices Reports Financial Results for Fourth Quarter and Fiscal Year Ended April 30, 2021 and Recent Developments

-- Recorded Fourth Quarter Revenue of $27.6 Million and Annual Revenue of $95.9 Million -- -- Achieved Four Consecutive Quarters of Operational Profitability During Fiscal 2021 -- -- Signed Approximately $148 Million in New Business Orders and Achieved a Year-End Backlog of $118 Million During

Avid Bioservices to Report Financial Results For Quarter and Fiscal Year Ended April 30, 2021 After Market Close on June 29, 2021

TUSTIN, Calif. , June 22, 2021 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and

Avid Bioservices Announces Completion of Redemption of Series E Convertible Preferred Stock

TUSTIN, Calif. , April 15, 2021 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO) (the “company”), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to

Sean Dodge

Sean Dodge Maricel.Felici… Fri, 03/19/2021 - 11:46 Sean Dodge RBC Capital Markets
Show more

Avid Bioservices Frequently Asked Questions

  • When was Avid Bioservices founded?

    Avid Bioservices was founded in 1981.

  • Who are Avid Bioservices key executives?

    Avid Bioservices's key executives are Joseph Carleone, Daniel Hart and Richard B. Hancock.

  • How many employees does Avid Bioservices have?

    Avid Bioservices has 211 employees.

  • What is Avid Bioservices revenue?

    Latest Avid Bioservices annual revenue is $59.7 m.

  • What is Avid Bioservices revenue per employee?

    Latest Avid Bioservices revenue per employee is $282.9 k.

  • Who are Avid Bioservices competitors?

    Competitors of Avid Bioservices include Just-Evotec Biologics, Skyepharma and Circassia.

  • Where is Avid Bioservices headquarters?

    Avid Bioservices headquarters is located at 2642 Michelle Dr #200, Tustin.

  • Where are Avid Bioservices offices?

    Avid Bioservices has an office in Tustin.

  • How many offices does Avid Bioservices have?

    Avid Bioservices has 1 office.